Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL661687 | 0.98 | ERCC5 (0.43) | RAB9AMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL27871718 | 0.93 | ERCC5 (0.43) | RAB9AMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL661571 | 0.91 | RAB9A (0.52) | RAB9AMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL7799733 | 0.91 | ALDH1A1 (0.42) | RAB9AMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL286969 | 0.88 | ALDH1A1 (0.42) | RAB9AMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL287219 | 0.87 | TSHR (0.42) | RAB9AMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL287773 | 0.87 | ALDH1A1 (0.39) | RAB9AMEN1KMT2AALDH1A1ERCC5 | |
| SCHEMBL659705 | 0.86 | ALDH1A1 (0.37) | RAB9AMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL287147 | 0.86 | KMT2A (0.57) | RAB9AMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL661019 | 0.85 | NPSR1 (0.43) | RAB9AMEN1KMT2AALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | claimed |
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | AGER, REN, AGT | RAB9A 2179/4885MEN1 1455/4885KMT2A 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.